Journal
GENE
Volume 644, Issue -, Pages 80-86Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.gene.2017.10.071
Keywords
Drug response prediction; High-risk; Multiple myeloma
Categories
Funding
- Research Fund at Rigshospitalet, Copenhagen, Denmark
- Danish Cancer Society, Copenhagen, Denmark [R152-A9822-16-S7]
- The Danish Cancer Society [R152-A9822] Funding Source: researchfish
Ask authors/readers for more resources
A Drug Response Prediction (DRP) score was developed based on gene expression profiling (GEP) from cell lines and tumor samples. Twenty percent of high-risk patients by GEP70 treated in Total Therapy 2 and 3A have a progression-free survival (PFS) of more than 10 years. We used available GEP data from high-risk patients by GEP70 at diagnosis from Total Therapy 2 and 3A to predict the response by the DRP score of drugs used in the treatment of myeloma patients. The DRP score stratified patients further. High-risk myeloma with a predicted sensitivity to melphalan by the DRP score had a prolonged PFS, HR = 2.4 (1.2-4.9, P = 0.014) and those with predicted sensitivity to bortezomib had a HR 5.7 (1.2-27, P = 0.027). In case of predicted sensitivity to bortezomib, a better response to treatment was found (P = 0.022). This method may provide us with a tool for identifying candidates for effective personalized medicine and spare potential non-responders from suffering toxicity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available